AstraZeneca Stock Leads 3 Cash Rich Shares Trading Below Fair Value

Global bond yields remain pressured by inflation risk and tight policy expectations. That keeps many investors focused on headline interest rate moves and short term swings. Quietly, it can leave some cash rich companies trading below fair value as attention drifts elsewhere. This article looks at the Undervalued Stocks Based On Cash Flows screener and highlights 3 stocks that combine strong cash flow potential with discounted valuations.

The stocks covered next are just a sample of what this idea can uncover, as the full screen surfaced 44 more companies with similarly interesting cash flow profiles that are not discussed here. To go further, identify and analyze your own highest conviction candidates by heading straight into the Undervalued Stocks Based On Cash Flows screener.

AstraZeneca is a large biopharmaceutical company that develops and sells prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines, and rare diseases. Its oncology and respiratory/immunology drugs such as Tagrisso, Imfinzi, Lynparza, Farxiga/Forxiga and Symbicort generate recurring, high margin cash flows that underpin its fit in an undervalued cash flow screen. The company reports about $61.4b of revenue from pharmaceuticals and has a market value of roughly £187.5b.

Investors looking at AstraZeneca today are really looking at a cash flow story backed by blockbuster oncology and respiratory drugs, supported by a deep late stage pipeline in areas like antibody drug conjugates and immuno oncology. The company is flagged as trading at a sizeable discount to a cash flow based fair value estimate, even after several years of strong earnings growth and a solid return on equity profile. That potential upside comes with real risks, including heavy dependence on a small group of key medicines and rising pricing pressure, especially from biosimilars and government cost controls. Recent mixed trial outcomes underline that not every pipeline bet will pay off. At the same time, positive data and new approvals in lung and breast cancer keep the longer term cash flow picture interesting for patient investors.

AstraZeneca’s blockbuster cash flows and pipeline continue to attract attention. The key question is how that story aligns with a cash flow based fair value estimate. Get the fuller picture in the DCF valuation analysis for AstraZeneca

Build your own cash flow shortlist around AstraZeneca

AstraZeneca and the two other stocks in this article all came from a single screen, but the real value is in building filters that fit your own approach. Use our flexible Screener to mix valuation, growth, balance sheet and risk filters, or jump straight into any of our curated Investing Ideas.

Foresight Group Holdings is an infrastructure and private equity manager that runs funds investing in real assets like renewable energy generation, social infrastructure and digital infrastructure. These assets create long term, contract backed cash flows that fit the Undervalued Stocks Based On Cash Flows theme. Most revenue comes from Real Assets at about £114.8 million, with Private Equity contributing about £50.1 million. The stock has a market cap of around £551 million.

Foresight Group Holdings may be worth a closer look for investors seeking exposure to renewable infrastructure cash flows packaged inside a listed asset manager. The Real Assets segment focuses on solar, onshore wind and battery storage projects that tend to generate relatively predictable, long duration cash streams. Recent results show revenue of £164.92 million and net income of £42.83 million. Strong ROE and an active share buyback programme indicate disciplined capital use; however, the setup carries risks, including fee pressure, potential regulatory changes around green assets and reliance on external borrowing. Investors assessing the relationship between AUM growth, contract backed fees and per share cash flow can incorporate these factors alongside the headline share price.

Foresight Group Holdings sits at the point where contract backed infrastructure cash flows meet listed equity valuation. See how its Real Assets and Private Equity engines feed through to per share cash generation in the analysis report for Foresight Group Holdings

BAE Systems is a large defense and aerospace group that designs and supports combat aircraft, ships, submarines, vehicles, munitions and electronic systems. Its Platforms & Services and Air segments, which together generate around £13.0b of revenue, are central to the screener theme because multi year production and servicing contracts can support relatively predictable cash flows. Electronic Systems adds a further £7.8b, with Maritime at £6.7b and Cyber & Intelligence at £2.4b, while the company’s market value is about £60.7b.

For investors looking at cash flow based value ideas, BAE Systems offers a mix of large, long term defense programs and through life support work that can support visibility on future cash generation. A sizeable order backlog, share buybacks and rising dividends show how that cash can be put to work; yet the stock still screens as trading below a DCF based fair value estimate. The flip side is real risk around heavy reliance on a handful of major government contracts, ongoing compliance scrutiny after the recent export related fine, and pressure on margins from supply chains and high capital spending. That balance between visible cash flows and concentrated risks is what makes BAE Systems worth a closer look for value oriented investors.

BAE Systems’ cash generation, order backlog and buybacks hint at a story that many investors may not be fully pricing in. See how those long term contracts feed into the DCF valuation analysis for BAE Systems

Seeking Alternatives Before Everyone Else?

Fresh ideas can move from quiet to breakout quickly. Screens filling with momentum today may be flying under the radar for now. Do not get caught dropping in late, get in early.

• Target resilient income by scanning companies with consistent payouts in the 5 dividend fortresses before yields compress and others rush toward the same cash generating stocks.
• Chase the next wave of AI infrastructure by tracking leaders inside the 55 AI infrastructure stocks while they are still building momentum before the wider market catches on.
• Hunt for agile automation winners using the curated 37 robotics and automation stocks to spot businesses riding the shift toward robotics solutions while it still matters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com